Depression

Cannabis use by pregnant women increased during pandemic

Monday, September 27, 2021 - 4:00pm

The study found that in the year before the pandemic, 6.75% of pregnant women were using cannabis in early pregnancy, and during the pandemic that rate rose to 8.14% of pregnant women.

Key Points: 
  • The study found that in the year before the pandemic, 6.75% of pregnant women were using cannabis in early pregnancy, and during the pandemic that rate rose to 8.14% of pregnant women.
  • The study did not determine why more pregnant women might be using cannabis.
  • "Our previous research has shown that the prevalence and frequency of prenatal cannabis use is increasing over time and that pregnant women are more likely to use cannabis if they are depressed, anxious, or have experienced trauma.
  • "The stay-at-home mandates, concerns about getting COVID-19, economic challenges, increased child care burden, and other difficult aspects of the pandemic could contribute to pregnant women feeling more stressed and depressed during this time," Young-Wolff added.

Live Online Event to Launch World’s First Video-Based Devotional App

Monday, September 27, 2021 - 3:42pm

Creators of Tome, will formally launch the worlds first daily video devotional app during a live online event on Sept. 28 at 12:00 p.m. CST.

Key Points: 
  • Creators of Tome, will formally launch the worlds first daily video devotional app during a live online event on Sept. 28 at 12:00 p.m. CST.
  • The Bible is for everyone - all people, at all times, in all places, in all situations, said Tome Co-Founder Chris Heaslip.
  • The past two years have presented a multitude of challenges including COVID-19, political and social unrest, natural disasters and more.
  • Tome will unveil its features and future plans during the Sept. 28 launch event.

Today's Inspired Latina Authors Share Inspirations of Timeless Mexican Artist Frida Kahlo; Special event celebrates artist's positive values on Hispanic community

Monday, September 27, 2021 - 2:00pm

"We don't know how powerful we are until we really get out there and tell our stories and connect with other women," she said.

Key Points: 
  • "We don't know how powerful we are until we really get out there and tell our stories and connect with other women," she said.
  • "The synergy with the authors was lovely because these Latinas are awe-inspiring women and Frida was, what I call 'the grandmother of inspiring Latina women.'
  • About Today's Inspired Latina Book Series:
    Today's Inspired Latina is an award-winning book series of inspiration and hope, a poignant collection of personal stories that will activate your passion.
  • Their goal is to ignite your career as an author and offer proven methods to transform your mission into a movement.

Greenbrook TMS Completes US$13.2 Million Bought Deal Public Offering

Monday, September 27, 2021 - 1:47pm

Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, is pleased to announce the closing of its previously-announced public offering (the Offering).

Key Points: 
  • Greenbrook TMS Inc. (TSX: GTMS) (NASDAQ: GBNH) (Greenbrook or the Company), a leading provider of Transcranial Magnetic Stimulation (TMS) therapy in the United States, is pleased to announce the closing of its previously-announced public offering (the Offering).
  • The Company intends to use the net proceeds from the Offering to fund its previously-announced acquisition of Achieve TMS East, LLC and Achieve TMS Central, LLC and for working capital and general corporate purposes.
  • Clarus Securities Inc. and Desjardins Securities Inc. served as independent financial advisors to the Company in connection with the Offering.
  • Greenbrook has provided more than 675,000 TMS treatments to over 19,000 patients struggling with depression.

DotCom Therapy and Goodside Health Collaborate to Address the Shortage of Mental Health Resources in Schools

Monday, September 27, 2021 - 2:00pm

Through this partnership, DotCom Therapy is providing pediatric teletherapy services and resources to extend Goodside Healths current in-school telemedicine service offerings that primarily focus on physical health.

Key Points: 
  • Through this partnership, DotCom Therapy is providing pediatric teletherapy services and resources to extend Goodside Healths current in-school telemedicine service offerings that primarily focus on physical health.
  • DotCom Therapys web-based teletherapy application, Zesh, helps address this shortage by providing counseling services to Goodside Health patients directly in their school nurses office.
  • Together, we provide increased access for students to address their mental health concerns with pediatric mental health resources from qualified professionals around the country.
  • Goodside Health partners with districts to bring on-demand telehealth and mental health services to schools at no cost to the district.

New K-12 Survey: Social and Emotional Learning Gains Awareness and Prioritization Amid COVID-19 Pandemic

Monday, September 27, 2021 - 1:45pm

Teachers also find that student confidence has plummeted, and it is easier for them to disengage from learning.

Key Points: 
  • Teachers also find that student confidence has plummeted, and it is easier for them to disengage from learning.
  • Throughout the last year and a half, many students have dealt with family losses and are fearful of COVID-19 and social interactions.
  • McGraw Hill is a learning science company that delivers personalized learning experiences that drive results for students, parents, educators and professionals.
  • We focus on educational equity, affordability and learning success to help learners build better lives.

Healthy Workforce Institute Succeeds in Ending Nurse Bullying

Monday, September 27, 2021 - 1:00pm

OLDSMAR, Fla., Sept. 27, 2021 /PRNewswire-PRWeb/ --The Healthy Workforce Institute, (HWI) http://www.healthyworkforceinstitute.com , released their 2021 Disruptive Research Behavior Research Report today that focuses on ending nurse bullying and workplace incivility.

Key Points: 
  • OLDSMAR, Fla., Sept. 27, 2021 /PRNewswire-PRWeb/ --The Healthy Workforce Institute, (HWI) http://www.healthyworkforceinstitute.com , released their 2021 Disruptive Research Behavior Research Report today that focuses on ending nurse bullying and workplace incivility.
  • ( https://www.jointcommissionjournal.com/article/S1553-7250(19)30392-7/pdf )
    However, incivility continues because healthcare leaders simply don't know how to deal with nurse bullying or destructive behavior, so they are often ignored.
  • Founded in 2011 by speaker, consultant and author, Dr. Renee Thompson, DNP, RN, CSP, The Healthy Workforce Institute has helped thousands of professionals stop bullying and disruptive workplace behaviors in the healthcare industry.
  • Through education and development, consulting, the Healthy Workforce Academy, free guides, workbooks, and more, the company's mission is to create a world where bullying and incivility are immediately rejected and kindness, respect, and professionalism become the new norm.

Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

Monday, September 27, 2021 - 12:30pm

NEW YORK, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the publication of the results from its lumateperone monotherapy Phase 3 clinical trial (ITI-007-404). The article, "Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial,” was published online in The American Journal of Psychiatry and is available here.

Key Points: 
  • The article, "Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial, was published online in The American Journal of Psychiatry and is available here .
  • Study 404 assesed the efficacy and safety of lumateperone as monotherapy in patients with bipolar I or bipolar II disorder experiencing a major depressive episode (bipolar depression).
  • This global study randomized 381 patients with moderate to severe depression symptoms to receive placebo or lumateperone 42 mg for 6 weeks.
  • Lumateperone is being investigated for the treatment of bipolar depression, major depressive disorder, and other neuropsychiatric and neurological disorders.

BetterLife Files Patent for TD-0148A for Treatment of Cluster Headaches and Related Disorders

Monday, September 27, 2021 - 1:00pm

BetterLife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application.

Key Points: 
  • BetterLife is developing one of the new compositions of 2-bromo-LSD (TD-0148A) covered by its newly filed provisional patent application.
  • BetterLife is already in advanced stages of GMP manufacturing TD-0148A and initiated the necessary preclinical IND-enabling studies for TD-0148A.
  • We are excited to be developing and bringing to market treatments addressing cluster headaches, neuropathic pain and range of mental health conditions, including depression, anxiety and PTSD, and related disorders.
  • BetterLifes pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency and insomnia.

Nikean Foundation announces $5 million gift to create a Psychedelic Psychotherapy Research Centre at Toronto’s University Health Network (UHN)

Monday, September 27, 2021 - 11:15am

Toronto, Ontario, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The Nikean Foundation (Nikean), a Toronto-based charitable foundation committed to the promotion of research and education in support of the beneficial use of psychedelic medicines, has announced a $5 million transformational gift today in support of psychedelic psychotherapy at the University Health Network (UHN).

Key Points: 
  • Toronto, Ontario, Sept. 27, 2021 (GLOBE NEWSWIRE) -- The Nikean Foundation (Nikean), a Toronto-based charitable foundation committed to the promotion of research and education in support of the beneficial use of psychedelic medicines, has announced a $5 million transformational gift today in support of psychedelic psychotherapy at the University Health Network (UHN).
  • The gift is the largest ever donation in support of psychedelic science and research in Canada.
  • By accepting this gift, UHN is sending a powerful message that Canada is serious about psychedelic research and tackling the existential mental health crisis affecting the masses.
  • Affiliated with UHNs Centre for Mental Health, the new Nikean Psychedelic Psychotherapy Research Centre will anchor Canadas thriving psychedelic innovation and academic research hub, leading to revolutionary advances in how Canada treats mental illness and end-of-life distress.